Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 38.50 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
36.50 38.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.72 -9.07 -8.00 45
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 38.50 GBX

Shield Therapeutics (STX) Latest News

More Shield Therapeutics News
Shield Therapeutics Investors    Shield Therapeutics Takeover Rumours

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date Time Title Posts
05/3/202106:36Shield Therapeutics: poised for a US licensing deal1,478
26/2/202113:08Shield Therapeutics 3,805
06/8/202020:59Shield Therapeutics: Poised for a US deal-
25/2/202014:28SYNECTICS9
22/2/202021:14Seagate Technology2,674

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-03-04 16:40:1338.0050,00019,000.00O
2021-03-04 16:35:0638.506,8922,653.42UT
2021-03-04 16:28:5238.0041.52O
2021-03-04 16:27:4538.002,500950.00O
2021-03-04 16:27:3838.0013,8565,265.28O
View all Shield Therapeutics trades in real-time

Shield Therapeutics (STX) Top Chat Posts

DateSubject
04/3/2021
08:20
Shield Therapeutics Daily Update: Shield Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 38.50p.
Shield Therapeutics Plc has a 4 week average price of 34.50p and a 12 week average price of 34.50p.
The 1 year high share price is 150p while the 1 year low share price is currently 34.50p.
There are currently 117,620,190 shares in issue and the average daily traded volume is 2,329,769 shares. The market capitalisation of Shield Therapeutics Plc is £45,283,773.15.
02/3/2021
09:40
shandypants2: Nico they did have significant interest but as per the Europe and China deals STX were always focused on achieving a substantial upfront payment, milestone payments and royalties. CEO has stated none of the massive pharma were that interested so discussions were held with smaller players. I suspect some could afford a substantial upfront payment so dropped out. 2 companies did progress to final stage discussions but were forced to drop out at the last minute (according to CEO one had covid issues and the other failed phase 3 on its main product). Going it alone could be very profitable. At only 2% it will generate US profits of $130m (would be only $30m via partner model). STX are expecting over $100m revenue in year 3 and $300m plus in year 5. My big issue is why didn't they think of this 18 months ago!!! The share price has declined c75% in the last 3 months so the placing is at a ridiculous price. Should have been over £1 if done 6 months ago
27/2/2021
09:12
pdt: I actually bought more yesterday and will get as many as I can get in the offer. Looking at their December slide pack they believe they can make annual profits at Year 5 of around £100m in the US. At a multiple of 10 that gives a market cap of £1 billion ignoring any value from Europe and China. However, there is execution risk and say they mess it up and achieve only 50% of those numbers, that's a potential £500m market cap. Today's market value with new shares is around £75m. The risk reward looks good to me and the shares were already discounting a placing when it was announced so I am expecting the share price to remain around 40p in these circumstances. As usual time will tell and I also take the point that the share price often does drift down to the placing price on a raise but I just doubt it in this case. As usual time will tell.
01/2/2021
10:09
innittowinit: Here is the latest summary from Edison published this morning; Shield Therapeutics: Beefing up for the US opportunity Shield Therapeutics’ (STX’s) shares fell sharply in December 2020 on the announcement that a US partnering deal would not be completed in 2020 and that the company is considering launching Accrufer itself in the US. We believe the market reaction has been overdone and the current share price fully discounts any value from the US and China opportunities. Until STX provides further clarity, we have continued to evaluate it based on a US partnering deal. Our modelling suggests an STX-led US launch could more than double longer-term shareholder value, but this is accompanied by increased near-term financial and investment risk, as STX will need to raise funds to establish a small but focused US marketing organisation. We value STX at £298.5m. Register to download the whole thing from the Edison website.
16/1/2021
20:31
lovewinshatelosses: That is a bit harsh t0pgrader - LTH's have a legitimate gripe here; the share price performance, driven by the well-documented failures to date of the management team, are not by any stretch of the imagination trivial IMO, nor would be a fundraise, if it is at a substantial dilutive cost to existing holders. I appreciate your point regarding the C4XD scenario - very similar to historic share price performance of 4D and more recently RENE (OK - they are more extreme examples of share price shrinkage, but the point still stands). A fair few others too of course. All potentially quite lucrative for well-timed trades, but stink for the LTH's. I first bought in here fairly recently around the early 80's; averaged up and then down a couple of times. Current average a shade over a quid. Only a small holding, but who likes to get calls and timings wrong?! My initial instinct was to just trade this one and thus far it looks like I should have trusted my gut. All that said, there are some very knowledgeable posters on here that seem to remain confident in this company, and my holding here is small enough that I am willing to let FOMO trump risk management, for the time being anyway. I have a top up price in mind if it hits and will probably just bottom draw this one if it comes down to it. Anyway GLA and lets hope RG or others of note are indeed loading up here.
15/1/2021
10:37
t0pgrader: This is probably the nearest thing I've seen to a one-way upside bet. Ignoring the US market altogether the share price is on F 2022 PE of just 11.5 which offers good fundamental value and provides serious downside protection. If STX complete a licence deal for the USA with a 3rd party (which would remove talk of a fundraise & deliver minimum $30m upfront payment) it would be absurd if the share price didnt at least revert to the status quo ante in Dec ie at least double the current level. furthermore, with the knowledge gained of the US market and the work done on developing their own go-to-market strategy the co is in a stronger negotiating position with the remaining parties. Or if STX go it alone in the USA the revenue per sale would be x3 higher and just 3% market share delivers PBT of $150m pa until patent expiry in 2035. The cost to do so is an equity raise of about £12m of which approx 60% should be covered by the institutional investors leaving a requirement of just c£5m from PIs and new institutions. PIs have been assured they will be able to purchase on same terms as institutions so no compulsory dilution. Hardly challenging or unattractive. The fallback option is a sub-optimal out licence deal which would bring a smaller upfront payment but it's still a deal that would bring substantial revenues that are not accounted for in the current market cap. Not long to wait - the CEO has committed to a decision by end March 21 Plus: STX expect to licence another territory in 2021 Plus: by eliminating the need for intravenous hospital treatment the product is a Covid beneficiary Plus: $11.4m royalty payment due from Ask once product is approved for sale in China (12 week additional study required with IBS sufferers) Plus: the CEO purchased £69,000 shares in Dec 20 at a share price 40%+ above the current level Plus: the CEO's Dec 2020 share options are only exercisable in 2021 in tranches starting at a market cap of £175m Vs £66m today Plus: company has sufficient cash until end 21 so no short-term keep the lights on placing
14/1/2021
17:08
shandypants2: Hi, before xmas i emailed the company and expressed my disappointment at a number of issues - the main one being i felt they had sabotaged their own share price by announcing the POTENTIAL need for fundraising before a decision had been made and why didn't they do it say in the Autumn when the share price was over 100% higher? I actually received a reply from the CEO directly (Tim Watts for those who may doubt me). Anyway in subsequent discussions Tim was very open and honest regarding the situation. Nothing he told me was price sensitive and is mainly covered in the Dec 2020 presentation. A quick summary of the main points are 1. STX are still in discussions with a number of US companies and there remains good interest 2. no decision has been made regarding way forward for US but it will be by end of Q1 2021. Both STX brokers felt rns had to mention potential cost of going it alone in US as questions would be asked 3. Tim expecting some revenues from US in Q2 2021 regardless of route to market 4. in US you can identify the doctors prescribing iron supplements etc so you can focus your efforts on these people 5. i mentioned US revenue estimates were quite conservative at only 2% of iron prescriptions - he agreed but felt a 5% figure was too large!! It is £900m profit a year!! 6. Norgine should soon be selling in Italy, Spain and France in 2021 and also in Oz and NZ once regulatory approval given - delayed due to covid. 7. China progressing and as per expected timescales 8. if a fundraise is required there will be an open offer too so existing shareholders can participate. He was very sure on that point as he felt it important.
06/1/2021
14:18
luisfrg: LATEST RESEARCHLatest corporate researchLatest tax enhanced reviewsSubscribe to our latest researchWHAT WE DOInvestment research servicesTax enhanced research servicesBespoke consulting servicesABOUTAbout Hardman & CoCase studiesThe teamNews, podcasts & insightsContact usOUR TEAMNEWS & EVENTSAbout Hardman & CoCase studiesThe teamNews, podcasts & insightsCONTACT US   COVID-19: - Our Commitment to Client Service & Investor Communications LIFE SCIENCESShield Therapeutics PlcReassessing the US opportunity06 JAN 2021 / CORPORATE RESEARCHBy Dr Martin Hall DOWNLOAD FULL REPORT STX is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru®/Accrufer® has been approved by the regulators in both Europe and the US. For various reasons, STX has been unable to secure a commercial partner for Accrufer in the US. Consequently, the board is now considering an STX-led launch option, thereby retaining all the US profits. Financial modelling shows the logic of this option, but it would necessitate financing the working capital requirements covering the next two years in the region of £25m-£30m. Strategy: STX’s strategy has been to out-license commercialisation rights to partners with appropriate expertise in target markets. Although this strategy has been successful in Europe and China, the company has not been able to secure a satisfactory deal for the US, which has necessitated a re-think.US options: During multiple US commercialisation discussions, potential partners have shared with STX management considerable intelligence about the US sales and marketing opportunity for Accrufer. Based on this information and its own research, the board has concluded that STX could launch Accrufer by itself.Financial implications: Financial modelling suggests that retention of the commercialisation rights and profits to Accrufer in the US results in substantially higher returns for shareholders. However, to achieve this, the company will need additional working capital of £25m-£30m for the next two years.Risks: Operationally, the main risk is that of execution, with little in-house commercial experience; however, STX has begun to address this by recruiting experienced US commercial managers. Finance will also be required, potentially through a combination of specialist debt and equity.Investment summary: Subject to financing being available, the STX-led option for Accrufer appears to be the best option for shareholders. The attributes and positioning off Accrufer are well-suited to the COVID-19 environment, eliminating the hospital attendance risk. The shares have over-reacted to the “lack of deal” news and should recover quickly once the uncertainty is removed.
22/12/2020
16:28
kop202: For STX.....its buy right and sit tight.....there arnt many AIM shares you can say that aboutThe free float is small so a big move up in the share price is coming and all that sold will play a nice big spread to the MM for the privilege of getting back on board.....the drop was painful.....but which do you prefer share price distress of FOMO....its always the way with AIM shares
19/12/2020
23:18
innittowinit: He'll have excercised the options to take advantage of the low share price as it means the tax (PAYE so income tax at 45% + 2% employees NI plus upto 13% employers NI depending in how the company treats such things) he has to pay on the gain at this price is so much lower than last week and he can now hold and when he sells, any further upside will be capital gains at 20% rather than the 50%+ he has just had to pay. Gain per share is current share price - 1.5p, so a healthy tax bill. it is all a balance of risk versus gain. He obviosuly thinks the share price is going to rebound with their efforts. Still haven't seen any of the pathetically hopeless NEDs buy any shares... New option issue is AGAIN horribly timed and whilst the triggers if achieved mean they will have done a good job from here, their communications are just so abysmally bad. Why not wait for at least a few weeks? Idiots. Presumably they've incentivised other team members on a salary pro-rata basis but we will never know as presumably none of those are PDMRs...
01/12/2020
09:28
ekcs: @nobbygnome #693 The sales last week and people's comments about it being negavtive made me curious so I've done some reading... Looking at various company announcements the former CEO put c. £300,000 into the IPO at 150p... so he quite a bit under water on that... and followed his money when warrants were exercised back in June 2017, again at 150p. Who knows how much he invested prior to becoming a plc. SO i guess the purchase you refer to represent relatively few shares (~90,000 out of >10m) and their sale is not going even going to get him into positive territory, nevermind make him rich!! As for options and their exercise - looking back at the various RNS announcements on such matters I reckon he might have upto north of 500,000 options IF he was allowed to retain any of them when he departed. If unexercised these will not be included in his stated holdings. The announcement from earlier last year around the 123,000 options was when the share price was c. 85p. There was no announcement of a sale at that time (I guess he was locked in officially or even unofficially as the founder and then CEO), so under the HMRC's rules he'd have had to pay the tax on the gain at the time of the gain, as it is PAYE. Again looking at the company's documentation and announcements around their schemes the options to executives/PDMIs get issued at 1.5p, so on 123,690 shares (the number referred to in your link) the value would have been around 100k, with tax due at the time of exercise at around 55% (check out HMRC rules on such share schemes and remember it is PAYE), so another £50k 'investment' give or take. Perhaps some of the sale last week was related to his options as usually ex-employees are given a period of time by their former employers to exercise any vested options post departure, so maybe he had reached his time limit and despite hoping they would get a deal announced within the timeframe, something is better than nothing if they simply expired. All that said, for me the important points (that any sensible person knows and inittowinit has also listed) are that: 1. whether he sold some last week to meet an investment requirement for his newly announced role or not, he is going to sell down at some point - we all would to diversify our risk if we held such a concentrated position 2. it looks like he has done this in a sensible way - rather than drippping shares into the market it seems to have been done via a 'book build' probably organised by one of the company's brokers 3. almost certainly the shares have been bought by one or more institutional buyers which is only positive. Hopefully with their new/additional purchases they will look to support the price and protect their investment The share price would of course be helped by a positive announcement (fingers, toes and everything else that can be is crossed), but it would also benefit from PIs not dripping a few thousand shares a day onto market makers, as those leaches simply lower the share price in reaction... The down is always steeper than the up trajectory!!
Shield Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
STX
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210305 07:44:18